5-MeO-MBDB
5-MeO-MBDB is a methoxy-substituted analog of the entactogen MBDB, sitting between entactogen and psychedelic profiles. It is essentially uncharacterised in humans and expected to produce gentle emotional effects possibly blended with mild psychedelia. It carries the serotonergic neurotoxicity and serotonin-syndrome concerns of the class.
01 Overview
5-MeO-MBDB is an obscure research compound derived from the benzodioxole entactogen MBDB by adding a methoxy substitution, a modification that in related series tends to add psychedelic character. Anecdotal and laboratory data are almost nonexistent.
No formal human pharmacology or toxicology exists. As a serotonergic benzodioxole it carries theoretical neurotoxicity and serotonin-syndrome risk. Likely covered by analog or psychoactive-substances legislation.
02 Mechanism
Methoxy-substituted benzodioxole predicted to act as a serotonin-preferring releaser with possible added 5-HT2A affinity, blending entactogenic and mild psychedelic effects.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 80–130 mg | Oral | Estimated; potency poorly defined |
| Common | 130–220 mg | Oral | Estimated, high uncertainty |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Gentle entactogenesisExpected soft emotional openness by analogy to MBDB. | Presumed mild-moderate | Unconfirmed | |
| Possible mild psychedeliaMethoxy substitution may add light psychedelic character. | Mild | Unconfirmed |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Serotonin syndromeTheoretical serious risk from serotonin release, especially in combination. | Life-threatening | Rare, elevated with serotonergic drugs | Unconfirmed | |
| Serotonergic neurotoxicityTheoretical axonal neurotoxicity shared with the MDMA/MBDB class. | Severe | Theoretical | Preclinical | |
| Uncharacterised safetyNo human toxicology exists for this obscure compound. | Moderate | Uncharacterised | Unconfirmed |